Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Tax Provisions (2017 - 2025)

Lisata Therapeutics' Tax Provisions history spans 11 years, with the latest figure at -$962000.0 for Q1 2025.

  • For Q1 2025, Tax Provisions fell 20.55% year-over-year to -$962000.0; the TTM value through Dec 2025 reached -$962000.0, down 20.55%, while the annual FY2025 figure was -$962000.0, 20.55% down from the prior year.
  • Tax Provisions reached -$962000.0 in Q1 2025 per LSTA's latest filing, down from -$798000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of -$798000.0 in Q1 2024 to a low of -$2.3 million in Q2 2023.
  • Average Tax Provisions over 3 years is -$1.4 million, with a median of -$962000.0 recorded in 2025.
  • The largest YoY upside for Tax Provisions was 20.55% in 2025 against a maximum downside of 20.55% in 2025.
  • A 3-year view of Tax Provisions shows it stood at -$2.3 million in 2023, then soared by 65.75% to -$798000.0 in 2024, then decreased by 20.55% to -$962000.0 in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Tax Provisions are -$962000.0 (Q1 2025), -$798000.0 (Q1 2024), and -$2.3 million (Q2 2023).